BPC-157 (Body Protection Compound-157) is a 15-amino-acid gastric pentadecapeptide with an extensive preclinical literature spanning gut healing, tendon repair, and neurological protection. KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH) with demonstrated NF-κB inhibitory and gut anti-inflammatory properties in IBD preclinical models. Both are under FDA 503A compounding review and listed for PCAC evaluation in July 2026.
Research reference only — all information on this page summarises peer-reviewed scientific literature and does not constitute medical advice. View full compound profiles: BPC-157 · KPV
Mechanism Comparison
BPC-157 (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is a synthetic 15-amino-acid peptide isolated from human gastric juice protein BPC. Its mechanisms span multiple pathways: it activates the FAK-paxillin signalling pathway to accelerate fibroblast migration and tissue repair; upregulates growth hormone receptor (GHR) expression in healing tissue; modulates nitric oxide (NO) synthesis via eNOS pathways; promotes angiogenesis through VEGF upregulation; and demonstrates direct cytoprotective effects on gastric and intestinal epithelium by stabilising mucosal integrity. KPV (Lys-Pro-Val) is a C-terminal tripeptide derived from alpha-MSH that retains the anti-inflammatory properties of the parent peptide via inhibition of the NF-κB signalling pathway — a master regulator of pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β). KPV can penetrate intestinal epithelial cells directly, offering potential for oral delivery to gut tissue.
Side-by-Side Attributes
| Attribute | BPC-157 | KPV |
|---|---|---|
| Sequence | 15-amino-acid gastric pentadecapeptide | Tripeptide: Lys-Pro-Val (C-terminal α-MSH fragment) |
| Molecular weight | ~1,419.5 Da | ~341.4 Da |
| Primary mechanism | FAK-paxillin / VEGF / eNOS / GHR — multi-pathway tissue protection | NF-κB inhibition → TNF-α, IL-6, IL-1β suppression |
| Main research indications | Gut healing, tendon repair, fracture, CNS, NSAID ulcer prevention | Inflammatory bowel disease (IBD), colitis, gut epithelial inflammation |
| Evidence depth | Extensive — 100+ preclinical publications; 1 Phase II GI trial (Croatia) | Limited — primarily murine IBD models; no published human trials |
| Human clinical data | Phase II trial (duodenal ulcer, Croatian cohort); no FDA-registered RCT | No published human Phase I/II trials as of 2026 |
| Oral bioavailability | Active orally in rodent models (stable in gastric environment) | Active orally in IBD models; direct epithelial penetration demonstrated |
| FDA 503A compounding | Under Review — PCAC July 23, 2026 | Under Review — PCAC July 23, 2026 |
| Development stage | Preclinical / early clinical | Preclinical |
Key Research Points
- 1Both BPC-157 and KPV are scheduled for FDA Pharmacy Compounding Advisory Committee (PCAC) review on July 23, 2026. The outcome will determine whether compounding pharmacies can continue to prepare these peptides for patient-specific prescriptions under the 503A bulk drug substances pathway.
- 2BPC-157 has a substantially deeper preclinical evidence base than KPV: over 100 peer-reviewed publications document its effects across gut healing, tendon repair, fracture healing, CNS neuroprotection, and NSAID-ulcer prevention models. KPV's evidence is narrower, primarily focused on murine colitis (TNBS and DSS-induced IBD) models.
- 3A key mechanistic distinction is scope: BPC-157 engages multiple signalling pathways simultaneously (FAK-paxillin, VEGF, eNOS, GHR) and shows activity across diverse tissue types. KPV is mechanism-focused — its primary characterized activity is NF-κB inhibition in intestinal epithelial cells, making it a more targeted anti-inflammatory tool for gut indications.
- 4Both peptides are orally active in preclinical models — an unusual property for peptides. BPC-157 demonstrates stability in gastric acid; KPV's small size (3 amino acids) contributes to stability and allows direct epithelial penetration without requiring systemic absorption.
- 5Researchers differentiating between the two should consider indication specificity: BPC-157 is the more appropriate research tool for multi-tissue repair scenarios, while KPV is more targeted to intestinal inflammatory pathways via NF-κB for IBD-specific research questions.
Frequently Asked Questions
What is the difference between BPC-157 and KPV for gut research?
BPC-157 is a 15-amino-acid gastric pentadecapeptide with broad gut-protective properties including mucosal cytoprotection, ulcer healing, and anti-inflammatory effects mediated through multiple pathways (FAK-paxillin, VEGF, eNOS). KPV is a tripeptide (Lys-Pro-Val) derived from alpha-MSH that targets the NF-κB inflammatory signalling pathway specifically in intestinal epithelial cells. BPC-157 has a larger preclinical evidence base across diverse gut pathology models; KPV has more targeted evidence specifically in IBD (colitis) models. Both are orally active in preclinical models.
Are BPC-157 and KPV both under FDA review in 2026?
Yes. Both BPC-157 and KPV are listed for FDA Pharmacy Compounding Advisory Committee (PCAC) evaluation on July 23, 2026. The PCAC review will assess whether these substances are appropriate for inclusion on the 503A bulk drug substances list. An unfavourable recommendation could restrict or eliminate their availability through US compounding pharmacies. Researchers and clinicians should track PCAC proceedings and any subsequent FDA rulemaking.
Which is better researched — BPC-157 or KPV?
BPC-157 has a substantially more extensive research literature — over 100 published preclinical studies across gut, musculoskeletal, neurological, and systemic models, plus one Phase II trial in a Croatian cohort. KPV has a narrower but focused literature primarily centred on intestinal inflammation (IBD colitis models). Neither compound has completed a multi-site FDA-registered randomised controlled trial.
Deep Dive
For extended mechanism analysis, trial data, and regulatory context, see the full research article:
BPC-157 Research 2026: What the Latest Studies Show →Full compound profile
BPC-157
Full compound profile
KPV